Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CATIE Suggests Zyprexa Useful As Initial Schizophrenia Treatment – NEJM

Executive Summary

Results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study suggest Lilly's Zyprexa may be well suited as initial therapy in the treatment of schizophrenia, according to an editorial accompanying the study

You may also be interested in...



CER Credibility Lies In Methodology For Studies, Physician Tells BIO

The credibility of comparative effectiveness research ultimately will be judged based on the methodology used to conduct the research, David Charles, associate professor and vice-chairman of neurology at Vanderbilt University Medical Center and chairman of the physician group Alliance for Patient Access, told attendees during a session at the Biotechnology Industry Organization International Convention.

CER Credibility Lies In Methodology For Studies, Physician Tells BIO

The credibility of comparative effectiveness research ultimately will be judged based on the methodology used to conduct the research, David Charles, associate professor and vice-chairman of neurology at Vanderbilt University Medical Center and chairman of the physician group Alliance for Patient Access, told attendees during a session at the Biotechnology Industry Organization International Convention.

FDA's U-Turn On Fanapt: Comparative Assessments Must Have Clinical Meaning

The review of Vanda’s Fanapt casts into relief the contours of FDA’s authority to consider comparative efficacy as a factor in drug approval decisions.

Related Content

Topics

UsernamePublicRestriction

Register

PS046341

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel